Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives

Abstract excerpt

There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined equally either by Multicolor Flow Cytometry (MFC) or by Next Generation Sequencing (NGS) technologies. At present, modern technologies allow to detect up to one on 104 or on 105 or even on 106 cells, depending on their throughput. MFC...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Myeloma Research and Treatments
• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors